TY - JOUR
T1 - Cardiac and pulmonary late effects do not negatively influence performance status and non-relapse mortality of children surviving five yr after autologous hematopoietic cell transplantation
T2 - Report from the EBMT Paediatric Diseases and Late Effects Working Parties
AU - Uderzo, Cornelio
AU - Pillon, Marta
AU - Tridello, Gloria
AU - Dini, Giorgio
AU - Urban, Christian
AU - Corti, Paola
AU - Zintl, Felix
AU - Fagioli, Franca
AU - Messina, Chiara
AU - Verdeguer, Amparo
AU - Faraci, Maura
AU - Fedeli, Sara
AU - Tana, Francesco
AU - Tichelli, André
AU - Passweg, Jakob
AU - Rovelli, Attilio
PY - 2009/9
Y1 - 2009/9
N2 - The current prospective study dealt with clinical outcome associated with pulmonary and cardiac late effects of AuHCT in children with malignancies. We prospectively evaluated 58 children, utilizing pulmonary function tests and cardiac shortening fraction, performed in pre-AuHCT phase and then annually. The overall five-yr survival was 68%. The five-yr cumulative incidence of lung and cardiac function impairment in survivors was 21% in both cases. None of the patients presented with restrictive or obstructive pulmonary pathology at the last follow-up and performance status for all survivors, ranged from 90% to 100%. The cumulative incidence of non-relapse mortality was 12.6% (range 6.3-25.3%), whereas relapse mortality was 19.7% (range 11.6-33.5). In conclusion, our study shows no significant deterioration in post-AuHCT pulmonary and cardiac function and in particular, no negative impact of lung and heart late effects on performance status and non-relapse mortality.
AB - The current prospective study dealt with clinical outcome associated with pulmonary and cardiac late effects of AuHCT in children with malignancies. We prospectively evaluated 58 children, utilizing pulmonary function tests and cardiac shortening fraction, performed in pre-AuHCT phase and then annually. The overall five-yr survival was 68%. The five-yr cumulative incidence of lung and cardiac function impairment in survivors was 21% in both cases. None of the patients presented with restrictive or obstructive pulmonary pathology at the last follow-up and performance status for all survivors, ranged from 90% to 100%. The cumulative incidence of non-relapse mortality was 12.6% (range 6.3-25.3%), whereas relapse mortality was 19.7% (range 11.6-33.5). In conclusion, our study shows no significant deterioration in post-AuHCT pulmonary and cardiac function and in particular, no negative impact of lung and heart late effects on performance status and non-relapse mortality.
KW - Autologous hematopoietic cell transplantation
KW - Cardiac late effects
KW - Childhood
KW - Performance status
KW - Pulmonary
UR - http://www.scopus.com/inward/record.url?scp=68849120961&partnerID=8YFLogxK
U2 - 10.1111/j.1399-3046.2008.01055.x
DO - 10.1111/j.1399-3046.2008.01055.x
M3 - Article
C2 - 18992061
AN - SCOPUS:68849120961
SN - 1397-3142
VL - 13
SP - 719
EP - 724
JO - Pediatric Transplantation
JF - Pediatric Transplantation
IS - 6
ER -